CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: To validate the significance of our findings for human CML, we addressed whether CD8+ CTLs can kill CD34+CD38– CML stem/progenitor cells derived from newly diagnosed chronic phase CML patients and whether this effect can be reverted in the presence of Tregs (Supplemental Table 2).